Get the Stockscreener App
21.78
0.05%
0.01
Neurogene Inc stock is traded at $21.78, with a volume of 125.83K.
It is up +0.05% in the last 24 hours and up +13.50% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$21.77
Open:
$21.27
24h Volume:
125.83K
Relative Volume:
0.63
Market Cap:
$310.63M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.14%
1M Performance:
+13.50%
6M Performance:
+37.41%
1Y Performance:
-46.24%
1-Day Range:
$21.27
$22.75
1-Week Range:
$20.72
$23.80
52-Week Range:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
21.78 | 310.49M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Craig Hallum | Buy |
| May-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Neurogene Inc. stock retracement – recovery analysisSmart Trend Analysis With Buy Point Cues - Newser
Can machine learning forecast Neurogene Inc. recoveryFree Fast Gaining Stock Screener Report - Newser
Chart based analysis of Neurogene Inc. trendsIntraday Signal Forecast for Fast Traders - Newser
How volatile is Neurogene Inc. stock compared to the marketExpert Picks Watchlist For Every Investor - jammulinksnews.com
Neurogene Inc. stock trend outlook and recovery pathFree Chart Driven High Reward Trading Setup - Newser
Neurogene (NGNE) to Release Earnings on Friday - Defense World
Order flow analysis tools used on Neurogene Inc.Short-Term Price Breakout Signal Analysis - Newser
Ranking Neurogene Inc. among high performing stocks via toolsConsistent Profit Signals with AI Models - Newser
What institutional investors are buying Neurogene Inc. stockDaily Trading Review That Work - jammulinksnews.com
Analysts Set Neurogene Inc. (NASDAQ:NGNE) PT at $46.17 - Defense World
Is Neurogene Inc. reversing from oversold territoryDaily Profit Watch With Forecast Confidence - Newser
What risks could impact Neurogene Inc. stock performanceDividend Strategy Summary With 10-Year Outlook - Newser
What makes Neurogene Inc. stock price move sharplyPortfolio Positioning Strategy With Timing - Newser
What are analysts’ price targets for Neurogene Inc. in the next 12 monthsBest Dividend Updates From AI Tools - jammulinksnews.com
Can trapped investors hope for a rebound in Neurogene Inc.AI Screener for Daily Stock Forecast - Newser
Screener Results Flag Neurogene Inc. as OversoldWatchlist for Smart Swing Trading Updated - metal.it
Why Neurogene Inc. stock attracts strong analyst attentionFree ROI Boosting Trade Opportunity Calendar - Newser
How Neurogene Inc. stock performs during market volatilityFree Access to Smart Investment Tips - Newser
Will Neurogene Inc. Hold Gains Into CloseHigh Accuracy Alerts for ROI Traders Detected - metal.it
How does Neurogene Inc. generate profit in a changing economyWealth Building Insights With Low Risk - jammulinksnews.com
Is Neurogene Inc. stock overvalued or undervaluedAchieve breakthrough profits with smart strategies - jammulinksnews.com
Does Neurogene Inc. stock perform well during market downturnsMassive stock growth - jammulinksnews.com
How does Neurogene Inc. compare to its industry peersInvest smarter with actionable trading signals - jammulinksnews.com
Published on: 2025-07-28 07:19:32 - Newser
Is it the right time to buy Neurogene Inc. stockFind market-beating stocks for your portfolio - jammulinksnews.com
What is the risk reward ratio of investing in Neurogene Inc. stockConsistent double returns - jammulinksnews.com
Neurogene Inc. Stock Support and Resistance Levels You Should KnowDaily Trade Opportunity - metal.it
What are the latest earnings results for Neurogene Inc.Invest smarter with data-backed insights - jammulinksnews.com
What markets is DRTSW expanding into Is Neurogene Inc. stock a good long term investment option - jammulinksnews.com
Is Neurogene Inc. a good long term investmentStrong return on investment - PrintWeekIndia
What drives Neurogene Inc. stock priceTremendous growth opportunities - PrintWeekIndia
Neurogene Inc. Stock Analysis and ForecastExplosive capital gains - PrintWeekIndia
Rett bet set includes Neurogene, Taysha gene therapies - BioWorld MedTech
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):